Tesamorelin (Egrifta): Compound Profile

Tesamorelin occupies a unique position in the PepMax catalog: it is the only molecule we ship that has been approved by the U.S. Food and Drug Administration for a human therapeutic indication. The original Egrifta was approved in November 2010, the twice-concentrated Egrifta SV in 2019, and the current commercial product Egrifta WR (an eight-times-concentrated F8 formulation that requires only weekly reconstitution) in March 2025^[12][13]. The compound has a fully published Phase 3 program, a Lancet HIV pivotal NAFLD trial, an FDA prescribing label, and a 15-year post-marketing safety record. None of those facts is true of any other peptide in the catalog.

That regulatory legitimacy is also the source of a constraint. Tesamorelin’s approved indication is narrow: reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Off-label interest — cognitive performance, non-HIV NAFLD/MASH, body recomposition in healthy adults — runs ahead of the data, and the label-defined safety constraints (active-malignancy contraindication, IGF-1 monitoring, glucose surveillance) apply regardless of indication. This profile is an attempt to describe what the molecule is, what the controlled clinical record actually shows, and where the popular framing departs from the published evidence.

Nothing in this article is a recommendation. Tesamorelin is supplied by PepMax under the slug tesamorelin for laboratory research use only. Human clinical use is governed by the Egrifta WR FDA prescribing information^[12] and a prescribing physician.

At a glance

Sequence and structural details derive from the original Theratechnologies non-clinical pharmacology paper^[11] and the FDA Egrifta WR label^[12].

What tesamorelin is

Tesamorelin is a synthetic peptide originally developed by Theratechnologies under the designation TH9507. It is structurally an analog of human growth-hormone-releasing hormone (GHRH), specifically the 44-amino-acid native form hGRF(1–44), modified by attaching a trans-3-hexenoic acid at the N-terminal tyrosine. The modification matters: native GHRH is rapidly cleaved by dipeptidyl peptidase-IV (DPP-IV) at the Tyr¹–Ala² bond, producing a near-immediately inactive metabolite. The hexenoyl group blocks DPP-IV access, extending the in-vivo half-life enough to make once-daily subcutaneous dosing biologically meaningful^[11][14].

Mechanistically, tesamorelin is a selectiveGHRH-receptor agonist — meaning it does not act through the ghrelin / GHS-R1a (growth-hormone secretagogue receptor) pathway used by compounds like ipamorelin, MK-677 (ibutamoren), and other ghrelin mimetics. The two pathways converge on pituitary growth-hormone release but differ in their pulsatility profile, IGF-1 dynamics, and side-effect signatures.

Mechanism

Tesamorelin binds the pituitary GHRH receptor on somatotrophs and activates cAMP/PKA signalling, leading to pulsatile release of endogenous growth hormone. The resulting GH pulse drives hepatic production of insulin-like growth factor 1 (IGF-1), which is the systemic mediator of most downstream metabolic effects. Critically, the physiological pulsatility of GH release is preserved — tesamorelin amplifies the endogenous rhythm rather than producing a sustained supraphysiological elevation. This is the rationale for IGF-1 elevation that is meaningful but bounded, rather than the unbounded elevation seen with exogenous recombinant human GH^[11][12].

Evidence map

The figure below summarizes the published tesamorelin evidence base by domain. Two domains carry the bulk of the regulatory weight: HIV-associated lipodystrophy (the approved indication) and HIV-associated NAFLD (the strongest off-label signal). All other domains are sparser.

Pivotal Phase 3 — HIV lipodystrophy

Falutz and colleagues (2007) randomized 412 HIV patients with abdominal fat accumulation 2:1 to tesamorelin 2 mg/day or placebo for 26 weeks. Tesamorelin selectively reduced visceral adipose tissue (≈ 15–17% vs placebo) with preserved subcutaneous fat, and improved triglycerides. The result was published in the New England Journal of Medicine^[1]. The 2010 JAIDS extension confirmed efficacy and safety over 52 weeks and demonstrated that benefit reversed when tesamorelin was withdrawn^[2]. The pooled analysis of the two pivotal Phase 3 trials (Falutz JCEM 2010, n ≈ 806) consolidated the VAT reduction finding^[3]. Stanley and colleagues (2012) reported that the visceral adiposity reduction was associated with an improved metabolic profile^[8]. These four papers are the regulatory substrate of the original 2010 FDA approval and the subsequent SV and WR approvals.

HIV-associated NAFLD

Stanley and colleagues (2014) published the first JAMA randomized evidence that 6 months of tesamorelin reduced hepatic lipid in HIV-infected adults with abdominal fat accumulation (median −2.0% vs +0.9% placebo, p = 0.003)^[4]. The pivotal trial in the indication, published in The Lancet HIVin December 2019, was a 12-month multicentre randomized double-blind placebo-controlled trial with paired liver biopsies: tesamorelin reduced hepatic fat fraction by an absolute −4.1% (approximately 37% relative reduction) and reduced fibrosis progression on biopsy^[5]. Subsequent mechanistic substudies (Fourman 2020 JCI Insight, 2021 Scientific Reports) showed upregulation of oxidative-phosphorylation gene sets, downregulation of inflammation and TGF-β / tissue-repair signatures, and declines in plasma TGFB1 and CSF1 that correlated with improved fibrosis-related scores^[6][7]. Stanley 2017 separately documented that VAT reduction with tesamorelin was associated with improved liver enzymes^[9].

Cognitive function (non-HIV)

Baker and colleagues (2012) conducted a 20-week randomized controlled trial of tesamorelin (1 mg/day) in 137 older adults including those with mild cognitive impairment, published in Archives of Neurology. The trial reported favorable effects on executive function with an approximately 117% rise in IGF-1^[10]. This is a single trial with a relatively small sample, has not been replicated, and has not advanced to a registration program. It supports treating tesamorelin’s cognitive signal as hypothesis-generating rather than established.

Safety profile

Across the pivotal program and the post-marketing record, the dominant safety observations are:

• IGF-1 elevation— on-target and label-monitored. The Egrifta WR label requires periodic IGF-1 monitoring with a defined ceiling above which dose interruption or discontinuation is indicated^[12].
• Glucose intolerance— small but real increases in fasting glucose and HbA1c are seen in clinical trials and are reflected in the FDA label as a warning. Pre-existing diabetes warrants particular attention^[3][12].
• Active malignancy— contraindicated. The IGF-1 axis and tumor biology are not separable.
• Injection-site reactions— the most common adverse event in the pivotal trials (erythema, pruritus, pain).
• Arthralgias and peripheral edema— consistent with GH-axis biology and reported in the pivotal trials^[1][14].

Egrifta, Egrifta SV, Egrifta WR

Three commercial formulations of tesamorelin have been approved by the FDA. They are the same active ingredient at different concentrations and reconstitution profiles.

• Egrifta (F1)— original 2010 approval. Daily injection, daily reconstitution.
• Egrifta SV (F4)— 2019 approval. Twice-concentrated formulation, daily reconstitution.
• Egrifta WR (F8)— March 25, 2025 approval. Eight-times concentrated vs original Egrifta; daily injection but only weekly reconstitution. Demonstrated bioequivalent to F1 by pharmacokinetic studies and patent-protected through 2033. This is the current U.S. commercial product^[13].

Egrifta SV experienced a U.S. supply disruption in early 2025 following a 2024 contract-manufacturer shutdown; supply was restored after FDA approved a Prior Approval Supplement on April 8, 2025, during the WR transition^[13].

Development and approval timeline

Limitations of the evidence base

• Indication-specific evidence. The pivotal Phase 3 program is in HIV-associated lipodystrophy. The strongest off-label signal (HIV-NAFLD) is also in the HIV setting. Translating to non-HIV populations requires a separate program; the announcement of one does not substitute for the data.
• Cognitive trial is unreplicated. Baker 2012 is the single peer-reviewed cognitive trial of any size in non-HIV populations. It has not been followed by a Phase 3 program and should be treated as hypothesis-generating.
• No cardiovascular outcomes trial. The lipid and adiponectin improvements in the HIV trials are surrogate endpoints. A powered CVOT for tesamorelin has not been completed.
• IGF-1 ceilings, not floors, are the safety frame.Researchers interpreting tesamorelin’s mechanism should remember that the label-defined safety constraint is keeping IGF-1 below a ceiling, not driving it as high as possible.
• Body recomposition data is absent.The popular off-label use case — healthy-adult body composition or “anti-aging” — is not supported by adequate randomized outcome data. Effects on VAT in HIV-lipodystrophy do not extrapolate to healthy adult body recomposition without a controlled trial in that population.

Off-label use, IGF-1, and what the label actually requires

Tesamorelin is the rare peptide where off-label discussion has to defer to a real FDA prescribing label rather than to a vacuum. The Egrifta WR label is explicit about three things every researcher considering off-label work should internalize:

• Periodic IGF-1 monitoring is required, with a defined ceiling for dose interruption or discontinuation.
• Active malignancy is a contraindication. The reasoning is on-target IGF-1 biology.
• Glucose intolerance is a labeled warning. Pre-existing diabetes warrants particular attention.

These constraints are not specific to the approved indication; they are properties of the molecule. Off-label work in non-HIV NAFLD, cognition, or body composition does not suspend the IGF-1, malignancy, or glucose constraints — it concentrates them in a population where the efficacy evidence is weaker.

Reconstitution & handling

Tesamorelin is supplied as a lyophilized powder. The Egrifta WR commercial formulation is reconstituted weekly and dosed daily; lyophilized research-grade powder shipped by PepMax should be handled like any peptide of comparable molecular weight. Reconstitute with bacteriostatic water (0.9% benzyl alcohol) for multi-day storage in solution, or sterile water for injectionwhen the bacteriostatic preservative is undesirable for a given research design. Mix gently; do not vortex. Store the lyophilized vial at −20 °C or below, protected from light and moisture; once reconstituted, refrigerate (2–8 °C) and use within the protocol-defined window. Avoid repeated freeze–thaw cycles.

For background on the analytical numbers on a peptide’s certificate of analysis — HPLC purity, mass-spectrometric identity confirmation, water content — see our companion methods articles on what ≥99% purity actually means and how we verify peptide purity.

Further reading

The bibliography below points to the primary papers and regulatory documents referenced in this profile. The Falutz 2007 NEJM paper^[1] and the Stanley 2019 Lancet HIV paper^[5] are the highest-yield primary readings; the Egrifta WR FDA label^[12] is the operational document for any clinical use.